PMC:7306567 / 2380-2626 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":84,"end":94},"obj":"Body_part"},{"id":"T4","span":{"begin":110,"end":114},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62860"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}

{"project":"LitCovid-PubTator","denotations":[{"id":"48","span":{"begin":51,"end":72},"obj":"Disease"},{"id":"49","span":{"begin":84,"end":122},"obj":"Disease"}],"attributes":[{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D009503"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:C563515"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T22","span":{"begin":61,"end":72},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T16","span":{"begin":108,"end":114},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":61,"end":72},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0001875"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T30","span":{"begin":34,"end":45},"obj":"NCBITaxon:1"},{"id":"T31","span":{"begin":84,"end":94},"obj":"CL:0000775"},{"id":"T32","span":{"begin":108,"end":114},"obj":"CL:0000084"},{"id":"T33","span":{"begin":213,"end":230},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T51311","span":{"begin":34,"end":45},"obj":"NCBITaxon:1"},{"id":"T81106","span":{"begin":84,"end":94},"obj":"CL:0000775"},{"id":"T17383","span":{"begin":108,"end":114},"obj":"CL:0000084"},{"id":"T96288","span":{"begin":213,"end":230},"obj":"CHEBI:35705;CHEBI:35705"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}

{"project":"2_test","denotations":[{"id":"32572532-25354514-47963394","span":{"begin":240,"end":241},"obj":"25354514"},{"id":"T48775","span":{"begin":240,"end":241},"obj":"25354514"}],"text":"sease affecting immunocompromised individuals with prolonged neutropenia, inherited neutrophil disorders or T cell defects, with the risk depending on the patients’ underlying disease and the type and duration of immunosuppressive therapy [1]. Pa"}